Jefferies Maintains Bullish View on Biogen (BIIB) After Positive Hemophilia Pipeline Feedback

Jefferies reiterated their Buy rating and $137 price target on Biogen (NASDAQ: BIIB) following positive feedback on its hemophilia pipeline from an industry meeting.

The firm comments, "At a national meeting on blood disorders, we note commentary from seven physicians who treat hemophilia patients was incrementally positive for BIIB’s long-acting coagulation factor programs (FVIII-Fc and FIX-Fc), although hemophilia sales remain upside to our current valuation. We continue to expect Phase 3 data in 2H12."

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $120.73 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• DA Davidson Starts Everus (ECG) at Buy